Moderna (NASDAQ:MRNA) Coverage Initiated at Berenberg Bank

Investment analysts at Berenberg Bank initiated coverage on shares of Moderna (NASDAQ:MRNA - Get Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage set a "hold" rating and a $42.00 price target on the stock. Berenberg Bank's target price suggests a potential upside of 12.63% from the stock's current price.

MRNA has been the topic of several other reports. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research note on Friday, November 8th. JPMorgan Chase & Co. decreased their price objective on Moderna from $70.00 to $59.00 and set an "underweight" rating for the company in a research report on Monday, November 4th. Piper Sandler restated an "overweight" rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a report on Monday. Royal Bank of Canada reiterated a "sector perform" rating and set a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Finally, The Goldman Sachs Group reduced their price target on Moderna from $178.00 to $139.00 and set a "buy" rating for the company in a research report on Monday, September 16th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and a consensus target price of $84.00.

Moderna Stock Down 5.6 %

NASDAQ MRNA traded down $2.22 during trading hours on Tuesday, reaching $37.29. 9,001,887 shares of the company traded hands, compared to its average volume of 4,765,200. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $14.35 billion, a PE ratio of -6.59 and a beta of 1.69. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a 50 day moving average of $57.82 and a two-hundred day moving average of $96.07.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the firm earned ($1.39) EPS. As a group, equities analysts expect that Moderna will post -9.43 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company's stock, valued at approximately $682,754. The trade was a 13.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.20% of the company's stock.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently modified their holdings of MRNA. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Moderna by 1.4% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company's stock worth $19,239,000 after buying an additional 3,978 shares in the last quarter. Toronto Dominion Bank increased its stake in Moderna by 23.7% in the 3rd quarter. Toronto Dominion Bank now owns 131,477 shares of the company's stock valued at $8,787,000 after buying an additional 25,177 shares during the last quarter. Geode Capital Management LLC grew its stake in Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Groupama Asset Managment boosted its holdings in shares of Moderna by 29.1% during the third quarter. Groupama Asset Managment now owns 21,838 shares of the company's stock worth $1,459,000 after acquiring an additional 4,920 shares during the period. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in Moderna by 1.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 114,335 shares of the company's stock valued at $7,641,000 after purchasing an additional 1,635 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.